Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTACT-01 in previously treated metastatic non-small cell lung cancer
jRCT2051200065Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jan 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Atezolizumab + cabozantinib with Docetaxel monotherapy (2 arms). Primary endpoint: Overall survival. Started Jan 2021; status: completed.
02
Drugs
atezolizumabcabozantinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051200065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200065.